Xenix Medical commenced full commercial launch for its Lux Expandable Lumbar Interbody Fusion System following receipt of FDA 510(k) marketing clearance.
Whereas traditional expandable devices incorporate bulky expansion mechanisms that occupy space typically reserved for bone graft material, Lux allows for significant post-expansion bone graft packing and features the company’s NanoACTIV surface technology to support postoperative bone growth throughout the device. NanoACTIV, an FDA-designated nanotechnology, comprises proprietary macro-, micro-, and nanoscale features that have been shown in vitro to elicit mesenchymal stem cell differentiation through the osteogenic lineage.
The device also incorporates the company’s signature NeoWave matrix architecture, featuring uniform edge-to-edge porosity and an internal serpentine wall structure that reduces stiffness, point loading, and, thus, the risk of subsidence.
Xenix has completed the Lux alpha phase and seeks to expand access to additional surgeons and distribution partners.
Xenix Medical commenced full commercial launch for its Lux Expandable Lumbar Interbody Fusion System following receipt of FDA 510(k) marketing clearance.
Whereas traditional expandable devices incorporate bulky expansion mechanisms that occupy space typically reserved for bone graft material, Lux allows for significant post-expansion bone...
Xenix Medical commenced full commercial launch for its Lux Expandable Lumbar Interbody Fusion System following receipt of FDA 510(k) marketing clearance.
Whereas traditional expandable devices incorporate bulky expansion mechanisms that occupy space typically reserved for bone graft material, Lux allows for significant post-expansion bone graft packing and features the company’s NanoACTIV surface technology to support postoperative bone growth throughout the device. NanoACTIV, an FDA-designated nanotechnology, comprises proprietary macro-, micro-, and nanoscale features that have been shown in vitro to elicit mesenchymal stem cell differentiation through the osteogenic lineage.
The device also incorporates the company’s signature NeoWave matrix architecture, featuring uniform edge-to-edge porosity and an internal serpentine wall structure that reduces stiffness, point loading, and, thus, the risk of subsidence.
Xenix has completed the Lux alpha phase and seeks to expand access to additional surgeons and distribution partners.
Copy to clipboard 
